{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Folate"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K192586",
    "Predicate Device Reference 510(k) Number(s)": [
        "K092740"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGN"
    ],
    "Summary Letter Date": "May 1, 2020",
    "Summary Letter Received Date": "May 4, 2020",
    "Submission Date": "May 5, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1295"
    ],
    "Regulation Name(s)": [
        "Folic acid test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Folic acid"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae Folate chemiluminescent immunoassay for quantitative determination of folic acid in human serum",
    "Indications for Use Summary": "Quantitative determination of folic acid in human serum to assist in the diagnosis and treatment of anemias, used in conjunction with other clinical or laboratory data",
    "fda_folder": "Clinical Chemistry"
}